Shots:
- Transition Bio has entered into a drug discovery collaboration & license option agreement with Voyager Therapeutics to identify & develop selective small molecules targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS) & frontotemporal dementia
- As per the deal, Transition Bio will discover & optimize TDP-43–targeting small molecules, after which Voyager may license exclusive global rights to develop & commercialize the program
- In return, Transition Bio will receive a single-digit million-dollar upfront payment & ~$500M in potential research, development, commercial, & net sales milestones, plus high single to low double-digit royalties on future net sales
Ref: GlobeNewsWire| Image: Transition Bio & Voyager Therapeutics | Press Release
Related News:- SanegeneBio Collaborates with Eli Lilly to Advance RNAi Therapeutics for Metabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
